Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi
| Autor: | Ferrario, A, Merli, F, Luminari, S, Stelitano, C, Mannina, D, Russo, M, Mazza, P, Marcheselli, L, Goldaniga, Mc, Federico, M, Baldini, L, Lombardo, M, Bagnuolo, A, Nunzi, M, Mastrullo, L, Fregoni, V, Centurioni, R, Giglio, G, Ginaldi, Lia, Riezzo, A, Fragasso, A, Caparrotti, G, Partesotti, G, Vallisa, D, Girmenia, Gp, Polimeno, G, Musolino, C. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Lymphoma B-Cell Neutropenia Cyclophosphamide Adolescent medicine.medical_treatment Context (language use) Gastroenterology Disease-Free Survival Young Adult Internal medicine Follicular phase Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Indolent non-follicular lymphomas chemotherapy Fludarabine Chemotherapy Hematology business.industry Not Otherwise Specified Remission Induction Anemia General Medicine Middle Aged Thrombocytopenia Surgery Italy Toxicity Female business Vidarabine medicine.drug |
| Popis: | Indolent non-follicular non-Hodgkin lymphomas (INFL) are a heterogeneous subset whose treatment has been poorly investigated. In this context we have evaluated the efficacy and safety of combined fludarabine and cyclophosphamide (FC) upfront therapy. Sixty-three patients with advanced INFL were enrolled in the study. Therapy consisted in FC combination (25 and 250 mg/m(2), i.v., respectively, for three consecutive days) every 28 days for six courses. After histological review, 61 patients (36 men, median age 64 years, range 40-70 years) were evaluated (22 small lymphocytic, 11 lymphoplasmacytic, 25 marginal zone and 3 CD5-negative non-Hodgkin lymphomas not otherwise specified). Further two patients were excluded for lack of essential data; six patients were withdrawn before the third cycle because of WHO grade III and IV toxicity. At the final evaluation, the overall response rate was 83% with 40.7% of complete remission. Intention-to-treat analysis showed that at the median follow-up of 36 months, overall survival, progression-free survival and failure-free survival were respectively 78%, 60% and 46%; remission duration among the 49 patients achieving complete remission/partial remission at the end of treatment was 65% (44-78) without significant differences between the main histotypes. The most frequent grade III and IV toxic events were haematological (neutropaenia 34%, anaemia 18% and thrombocytopaenia 11%) and infectious (10%). FC is effective for advanced untreated INFL. Early deaths and haematological toxicity suggest careful patient selection and monitoring. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|